12:22:57 EDT Wed 17 Apr 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:CBAY from 2023-04-18 to 2024-04-17 - 40 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-22 09:18U:CBAYNews ReleaseGilead Sciences Announces Completion of Acquisition of CymaBay
2024-03-04 08:00U:CBAYNews ReleaseCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
2024-02-28 16:45U:CBAYNews ReleaseCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
2024-02-21 17:43U:CBAYNews ReleaseThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
2024-02-20 16:05U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-12 08:45U:CBAYNews ReleaseCymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
2024-02-12 08:30U:CBAYNews ReleaseGilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
2024-01-31 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Participate in Upcoming Investment Conferences
2024-01-16 16:29U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 08:00U:CBAYNews ReleaseNew Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
2024-01-02 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
2023-12-18 16:05U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-15 08:00U:CBAYNews ReleaseCymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
2023-11-17 16:15U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-13 08:00U:CBAYNews ReleaseCymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting ‚ ®
2023-11-07 16:04U:CBAYNews ReleaseCymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
2023-11-06 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Present at Upcoming Investment Conferences
2023-11-01 08:00U:CBAYNews ReleaseCymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
2023-10-31 16:05U:CBAYNews ReleaseCymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
2023-10-23 16:05U:CBAYNews ReleaseCymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
2023-10-23 08:00U:CBAYNews ReleaseSeladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
2023-10-18 08:00U:CBAYNews ReleaseCymaBay ¢ € ™s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting ‚ ® 2023
2023-10-16 16:05U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-21 08:00U:CBAYNews ReleaseCymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
2023-09-15 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
2023-09-14 16:58U:CBAYNews ReleaseCymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-09-11 22:15U:CBAYNews ReleaseCymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
2023-09-11 06:00U:CBAYNews ReleaseCymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
2023-09-07 07:00U:CBAYNews ReleaseCymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
2023-09-06 16:05U:CBAYNews ReleaseCymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
2023-08-28 16:29U:CBAYNews ReleaseCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-10 16:04U:CBAYNews ReleaseCymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update
2023-08-10 08:00U:CBAYNews ReleaseCymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase
2023-08-03 16:05U:CBAYNews ReleaseCymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023
2023-06-21 03:00U:CBAYNews ReleaseCymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
2023-06-07 02:00U:CBAYNews ReleaseCymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress ¢ „ ¢ 2023
2023-05-15 16:04U:CBAYNews ReleaseCymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-10 08:00U:CBAYNews ReleaseCymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
2023-05-09 08:00U:CBAYNews ReleaseCymaBay Names Harish Shantharam Chief Financial Officer
2023-04-21 08:00U:CBAYNews ReleaseCymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)